Jennie Ruelas Castillo

A DNA vaccine targeting Mtb persisters reduces TB treatment duration in mice and elicits similar immune responses in macaques.

This study uses a mouse model of TB infection to investigate fibrosis mechanisms, finding persistent inflammatory macrophages and elevated matrix remodeling enzymes during treatment.

This study shows that targeting CCRL2 with an antibody-drug conjugate improves TB treatment in mice by reducing inflammation and enhancing immune responses.

This study evaluates telacebec's contribution to combination therapies against two M. tuberculosis strains in a murine model, finding synergistic effects against HN878 and antagonistic effects against H37Rv.

This study evaluates two compounds that reduce triglyceride content in Mtb-infected macrophages but finds they do not reduce bacterial burden or inflammation in infected mice.

This paper evaluates the adjunctive effect of the HO-1 inhibitor stannsoporfin in combination with a novel MDR-TB regimen in a murine model, showing reduced lung bacillary burden but no effect on microbiological relapse.